Minapharm PharmaceuticalsCAI:MIPH -0.27%41 PS Ratio is 1.23 as of Jul. 13, 2026, which is 112% above its 10-year median of 0.58. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 955 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 70.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Minapharm Pharmaceuticals's share price is E£698.08.
Minapharm Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was E£567.46. Hence, Minapharm Pharmaceuticals's PS Ratio for today is 1.23.
Warning Sign:
Minapharm Pharmaceuticals stock PS Ratio (=1.2) is close to 5-year high of 1.23.
The historical rank and industry rank for Minapharm Pharmaceuticals's PS Ratio or its related term are showing as below:
CAI:MIPH'
s PS Ratio Range Over the Past 10 Years
Min: 0.32 Med: 0.58 Max: 1.23
Current: 1.23
During the past 5 years, Minapharm Pharmaceuticals's highest PS Ratio was 1.23. The lowest was 0.32. And the median was 0.58.
CAI:MIPH's PS Ratio is ranked better than 70.79% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs CAI:MIPH: 1.23
During the past 5 years, Minapharm Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 27.40% per year. The lowest was 22.60% per year. And the median was 25.00% per year.
Back to Basics: PS Ratio
Minapharm Pharmaceuticals (CAI:MIPH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Minapharm Pharmaceuticals PS Ratio Related Terms
Minapharm Pharmaceuticals PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Minapharm Pharmaceuticals's Share Price of today is E£698.08. Minapharm Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£567.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Minapharm Pharmaceuticals (CAI:MIPH) has a PS Ratio of 1.23 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Minapharm Pharmaceuticals and its competitors. This is 112% above median its historical median of 0.58. Over the past decade, Minapharm Pharmaceuticals' PS Ratio has ranged from 0.32 to 1.23. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #279 out of 955 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Minapharm Pharmaceuticals' PS Ratio too high?
Minapharm Pharmaceuticals' current PS Ratio of 1.23 is 112% above median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 1.23. The Drug Manufacturers industry median PS Ratio is 2.30. Minapharm Pharmaceuticals' value of 1.23 is 46.5% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #279 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #279 out of 955 companies for PS Ratio. This puts Minapharm Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 2.30. Minapharm Pharmaceuticals' value of 1.23 is 46.5% below this benchmark. Historically, Minapharm Pharmaceuticals' own PS Ratio has ranged from 0.32 to 1.23 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.30, Minapharm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current PS Ratio of 1.23 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current PS Ratio is 1.23, which is 112% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current PS Ratio is 1.23, which is 112% above median its 10-year median of 0.58 and 46.5% below the Drug Manufacturers industry median of 2.30. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current PS Ratio is 1.23 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
PS Ratio: 1.23 (112% above median its 10-year median of 0.58)
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
Industry Position: 46.5% below the Drug Manufacturers median (#279 of 955)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
